Staphylococcus aureus infective endocarditis: Diagnosis and management guidelines

Internal Medicine Journal

Volumn 35, Issue SUPPL. 2, 2005, Pages

  Murray, R J ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Endocarditis; Evidenced based guidelines; Infective endocarditis; Staphylococcus aureus

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; FLUCLOXACILLIN; FUSIDIC ACID; GATIFLOXACIN; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLONE DERIVATIVE; RIFAMPICIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; BACTERIAL ENDOCARDITIS; CLINICAL FEATURE; CONTINUOUS INFUSION; DRUG MEGADOSE; HUMAN; INCIDENCE; JAUNDICE; NEPHROTOXICITY; NUCLEIC ACID ANALYSIS; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; THROMBOPHLEBITIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; HEART VALVE; HEART VALVE REPLACEMENT; ISOLATION AND PURIFICATION; PRACTICE GUIDELINE; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; ECHOCARDIOGRAPHY; ENDOCARDITIS, BACTERIAL; HEART VALVE PROSTHESIS IMPLANTATION; HEART VALVES; HUMANS; PRACTICE GUIDELINES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33645805906     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1444-0903.2005.00978.x     Document Type: Review

References (207)

1. Espersen F, Frimodt-Moller N. Staphylococcus aureus endocarditis: a review of 119 cases. Arch Intern Med 1986; 146: 1118-21.
2. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23: 255-9.
3. Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am 2002; 16: 413-35.
4. Cabell CH, Jollis JG, Peterson GE, Corey GR, Anderson DJ, Sexton DJ et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002; 162: 90-4.
5. Sanabria TJ, Alpert JS, Goldberg R, Pape LA, Cheeseman SH. Increasing frequency of staphylococcal infective endocarditis: experience at a university hospital, 1981 through 1988. Arch Intern Med 1990; 150: 1305-9.
6. Watanakunakorn C, Burkert T. Infective endocarditis at a large community teaching hospital, 1980-1990: a review of 210 episodes. Medicine (Baltimore) 1993; 72: 90-102.
7. Sandre RM, Shafran SD. Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis 1996; 22: 276-86.
8. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345: 1318-30.
9. Cabell CH, Abutryn E. Progress towards a global understanding of infective endocarditis: early lessons from the International Collaboration on Endocarditis investigation. Infect Dis Clin North Am 2002; 16: 255-72.
10. Mouly S, Ruimy R, Launay O, Arnoult F, Brochet E, Trouillet J et al. The changing clinical aspects of infective endocarditis: descriptive review of 90 episodes in a French teaching hospital and risk factors for death. J Infect 2002; 45: 246-56.
11. Fowler VG Jr, Li J, Corey GR, Boley J, Marr KA, Gopal AK et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997; 30: 1072-8.
12. Watanakunakorn C. Staphylococcus aureus endocarditis at a community teaching hospital, 1980-1991. Arch Intern Med 1994; 154: 2330-5.
13. Fowler VG Jr, Sanders LL, Kong LK, McClelland RS, Gottlieb GS, Li J et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999; 28: 106-14.
14. Roder BL, Wandall DA, Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl VT. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159: 462-9.
15. John MDV, Hibberd PL, Karchmer AW, Sleeper LA, Calderwood SB. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis 1998; 26: 1302-9.
16. Wilson R, Hamburger M. Fifteen year's experience with Staphylococcus septicemia in a large city hospital: analysis of 55 cases in the Cincinnati General Hospital 1940-1955. Am J Med 1957; 22: 437-57.
17. Nolan CM, Beatty HN. Staphylococcus aureus bacteremia: current clinical patterns. Am J Med 1976; 60: 495-500.
18. Watanakunakorn C, Baird IM. Staphylococcus aureus bacteremia and endocarditis associated with a removable infected intravenous device. Am J Med 1977; 63: 253-6.
19. Mirimanoff RO, Glauser MP. Endocarditis during Staphylococcus aureus septicemia in a population of non-drug addicts. Arch Intern Med 1982; 142: 1311-13.
20. Gransden WR, Eykeyn SJ, Phillips I. Staphylococcus aureus bacteraemia: 400 episodes in St. Thomas's Hospital. BMJ 1984; 288: 300-3.
21. Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987; 9: 891-907.
22. Bayer AS, Lam K, Ginzton L, Norman DC, Chiu CY, Ward JI. Staphylococcus aureus bacteremia: clinical, serologic, and echocardiographic findings in patients with and without endocarditis. Arch Intern Med 1987; 147: 457-62.
23. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993; 16: 567-73.
24. Fowler VG Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27: 478-86.
25. Marr KA, Kong LK, Fowler VG Jr, Gopal A, Sexton DJ, Conlon PJ et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998; 54: 1684-9.
26. Mylotte JM, Tayara A. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 2000; 31: 1170-4.
27. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002; 162: 25-32.
28. Fowler VG Jr, Olsen MK, Corey R, Woods CW, Cabell CH, Reller B et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066-72.
29. Chang FY, MacDonald BB, Peacock JE Jr, Musher DM, Triplett P, Mylotte JM et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82: 322-32.
30. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-8.
31. Kainer M, Slavin M, Chua J, Goutzmanis J, Kucers A. Community-acquired Staphylococcus aureus bacteremia: clinical features and complications [abstract K206]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995; San Francisco, CA. Washington DC: American Society for Microbiology; 1995: 325.
32. O'Kane GM, Gottlieb T, Bradbury R. Staphylococcal bacteraemia: the hospital or the home? A review of Staphylococcus aureus bacteraemia at Concord Hospital in 1993. Aust NZ J Med 1998; 28: 23-7.
33. Blyth CC, Darragh H, Whelan A, O'Shea JP, Beaman MH, McCarthy JS. Evaluation of guidelines for the management of Staphylococcus aureus bacteraemia. Intern Med J 2002; 32: 224-32.
34. Levine DP, Crane LR, Zervos MJ. Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. Rev Infect Dis 1986; 8: 374-96.
35. Marantz PR, Linzer M, Feiner CJ, Feinstein SA, Kozin AM, Friedland GH. Inability to predict diagnosis in febrile intravenous drug abusers. Ann Intern Med 1987; 106: 823-8.
36. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users: prognostic features in 102 episodes. Ann Intern Med 1992; 117: 560-6.
37. Mathew J, Addai T, Anand A, Morrobel A, Maheshwari P, Freels S. Clinical features, site of involvement, bacteriologic findings and outcome of infective endocarditis in intravenous drug users. Arch Intern Med 1995; 155: 1641-8.
38. Miro JM, del Rio A, Mestres CA. Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. Cardiol Clin 2003; 21: 167-84.
39. Watanakunakorn C, Baird IM. Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am J Med Sci 1977; 273: 133-9.
40. Tuazon CU, Sheagran JN. Increased staphylococcal carrier rate among narcotic addicts. J Infect Dis 1974; 129: 725-7.
41. Tuazon CU, Sheagren JN. Staphylococcal endocarditis in parenteral drug abusers: source of the organism. Ann Intern Med 1975; 82: 788-90.
42. Crane LR, Levine DP, Zervos MJ, Cummings G. Bacteremia in narcotic addicts at the Detroit Medical Center: microbiology, epidemiology, risk factors and empiric therapy. Rev Infect Dis 1986; 8: 364-73.
43. Reisberg B. Infective endocarditis in the narcotic addict. Prog Cardiovasc Dis 1979; 22: 193-204.
44. Manoff SB, Vhlahov D, Herskowitz A, Solomon L, Munoz A, Cohn S et al. Human immunodeficiency virus infection and infective endocarditis among injecting drug users. Epidemiology 1996; 7: 563-5.
45. Spijkerman IJ, van Ameijden EJ, Mientjes GH, Coutinho RA, van den Hoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol 1996; 49: 1149-54.
46. Ribera E, Gomez-Jiminez J, Cortes E, del Valle O, Planes A, Gonzales-Alujas MT et al. Effectiveness of cloxacillin with and without gentamicin in short term therapy for right-sided Staphylococcus aureus endocarditis. Ann Intern Med 1996; 125: 969-74.
47. Heldman AW, Hartert TV, Ray SC, Dauod EG, Kowalski TE, Pompili VJ et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in intravenous drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101: 68-76.
48. Frimodt-Moller N, Espersen F, Rosdahl VT. Antibiotic treatment of Staphylococcus aureus endocarditis. A review of 119 cases. Acta Med Scand 1987; 222: 175-82.
49. Fernandez-Guerrero ML, Verdejo C, Azofra J, de Gorgolas M. Hospital-acquired infectious endocarditis not associated with cardiac surgery: an emerging problem. Clin Infect Dis 1995; 20: 16-23.
50. Rohmann S, Erbel R, Mohr-Kahaly S, Meyer J. Use of transesophageal echocardiography in the diagnosis of abscess in infective endocarditis. Eur Heart J 1995; 16: 54-62.
51. Bayer AS, Norman DC. Valve site-specific pathogenetic differences between right-sided and left-sided bacterial endocarditis. Chest 1990; 98: 200-5.
52. Di Nubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in intravenous drug users. Ann Intern Med 1994; 121: 873-6.
53. Roder BL, Wandall DA, Espersen F, Frimodt-Moller N, Skinhoj P, Rosdahl VT. Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. Am J Med 1997; 102: 379-86.
54. Corr P, Wright M, Handler LC. Endocarditis-related cerebral aneurysms: radiologic changes with treatment. AJNR Am J Neuroradiol 1995; 16: 745-8.
55. Von Reyn CF, Levy BS, Arbeit RD, Friedland G, Crumpacker CS. Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med 1981; 94: 505-18.
56. Majumdar A, Chowdhary S, Ferreira MA, Hammond LA, Howie AJ, Lipkin GW et al. Renal pathological findings in infective endocarditis. Nephrol Dial Transplant 2000; 15: 1782-7.
57. Coleman DL, Horwitz RI, Andriole VT. Association between serum inhibitory and bactericidal concentrations and therapeutic outcome in bacterial endocarditis. Am J Med 1982; 73: 260-7.
58. Tuazon CU, Sheagren JN. Teichoic acid antibodies in the diagnosis of serious infections with Staphylococcus aureus. Ann Intern Med 1976; 84: 543-6.
59. Shrestha NK, Tuohy MJ, Hall GS, Isada CM, Procop GW. Rapid identification of Staphylococcus aureus and the mecA gene from BacT/ALERT blood culture bottles by using the LightCycler system. J Clin Microbiol 2002; 40: 2659-61.
60. Oliveira K, Procop GW, Wilson D, Coull J, Stender H. Rapid identification of Staphylococcus aureus directly from blood cultures by fluorescence in situ hybridization with peptide nucleic acid probes. J Clin Microbiol 2002; 40: 247-51.
61. Millar B, Moore J, Mallon P, Xu J, Crowe M, Mcclurg R et al. Molecular diagnosis of infective endocarditis - a new Duke's criterion. Scand J Infect Dis 2001; 33: 673-80.
62. Bosshard PP, Kronenberg A, Zbinden R, Ruef C, Bottger EC, Altwegg M. Etiologic diagnosis of infective endocarditis by broad-range polymerase chain reaction: a 3-year experience. Clin Infect Dis 2003; 37: 167-72.
63. Shively BK, Gurule FT, Roldan CA, Leggett JH, Schiller NB. Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis. J Am Coll Cardiol 1991; 18: 391-7.
64. Purnell PW, O'Brien DP, Appelbe AF, Athan E. Nosocomial Staphylococcus aureus bacteraemia: a high incidence of endocarditis found on transesophageal echocardiography. Intern Med J 2001; 31: A23.
65. Erbel R, Rohmann S, Drexler M, Mohr-Kahaly S, Gerharz CD, Iversen S et al. Improved diagnostic value of echocardiography in patients with infective endocarditis by transesophageal approach: a prospective study. Eur Heart J 1988; 9: 43-53.
66. Mugge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol 1989; 14: 631-8.
67. Daniel WG, Mugge A, Martin RP, Lindert O, Hausmann D, Nonnast-Daniel B et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 1991; 324: 795-800.
68. Lowry RW, Zoghbi WA, Baker WB, Wray RA, Quinones MA. Clinical impact of transesophageal echocardiography in the diagnosis and management of infective endocarditis. Am J Cardiol 1994; 73: 1089-91.
69. Shapiro SM, Young E, De Guzman S, Ward J, Chiu CY, Ginzton LE et al. Transesophageal echocardiography in diagnosis of infective endocarditis. Chest 1994; 105: 377-82.
70. Birmingham GD, Rahko PS, Ballantyne F. Improved detection of infective endocarditis with transesophageal echocardiography. Am Heart J 1992; 123: 774-81.
71. San Roman JA, Vilacosta I, Zamorano JL, Almeria C, Sanchez-Harguindey L. Transesophageal echocardiography in right-sided endocarditis. J Am Coll Cardiol 1993; 21: 1226.
72. Georgeson R, Liu M, Bansal RC. Transesophageal echocardiographic diagnosis of eustachian valve endocarditis. J Am Soc Echocardiogr 1996; 9: 206-8.
73. Daniel WG, Mugge A, Grote J, Hausmann D, Nikutta P, Laas J et al. Comparison of transthoracic and transesophageal echocardiography for the detection of abnormalities of prosthetic and bioprosthetic valves in the mitral and aortic positions. Am J Cardiol 1993; 71: 210-15.
74. Habib G, Guidon C, Tricoire E, Djiane V, Monties JR, Luccioni R. Papillary muscle rupture caused by bacterial endocarditis: role of transesophageal echocardiography. J Am Soc Echocardiogr, 1994; 7: 79-81.
75. De Castro S, d'Amati G, Cartoni D, Venditti M, Magni G, Gallo P et al. Valvular perforation in left-sided infective endocarditis: a prospective echocardiographic evaluation and clinical outcome. Am Heart J 1997; 134: 656-64.
76. Rosen AB, Fowler VG Jr, Corey GR, Downs SM, Biddle AK, Li J et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med 1999; 130: 810-20.
77. Daniel WG, Erbel R, Kasper W, Visser CA, Engberding R, Sutherland GR et al. Safety of transesophageal echocardiography: a multicenter survey of 10 419 examinations. Circulation 1991; 83: 817-21.
78. Vuille C, Nidorf M, Weyman AE, Picard MH. Natural history of vegetations during successful treatment of endocarditis. Am Heart J 1994; 128: 1200-9.
79. Rohmann S, Erbel R, Darius H, George G, Makowski T, Zotz R et al. Prediction of rapid versus prolonged healing of infective endocarditis by monitoring vegetation size. J Am Soc Echocardiogr 1991; 4: 465-74.
80. Bayer AS, Blomquist IK, Bello E, Chiu CY, Ward JI, Ginzton LE. Tricuspid valve endocarditis due to Staphylococcus aureus: correlation of two-dimensional echocardiography with clinical outcome. Chest 1988; 93: 247-53.
81. Han D, Lee KS, Franquet T, Muller NL, Kim TS, Kim H et al. Thrombotic and nonthrombotic pulmonary arterial embolism: spectrum of imaging findings. Radiographics 2003; 23: 1521-39.
82. Durack DT, Lukes AS, Bright DK. Duke Endocarditis Service. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med 1994; 96: 200-9.
83. Bayer AS, Bolger AF, Taubert KA, Wilson W, Steckelberg J, Karchmer AW et al. Diagnosis and management of infective endocarditis and its complications. Circulation 1998; 98: 2936-48.
84. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci and HACEK organisms. JAMA 1995; 274: 1703-13.
85. Rubinstein E, Carbon C, the Endocarditis Working Group of the International Society of Chemotherapy. Staphylococcal endocarditis - recommendations for therapy. Clin Microbiol Infect 1998; 4 Suppl 3: S27-33.
86. Simmons NA, Ball AP, Eykeyn SJ, Littler WA, McGowan DA, Oakley CM et al. Antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. Heart 1998; 79: 207-10.
87. Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD et al. Antimicrobial resistance in Staphylococcus aureus in teaching hospitals, 1989-1999. Microb Drug Resist 2003; 9: 155-60.
88. Sande MA, Johnson ML. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis 1975; 131: 367-75.
89. Sande MA, Courtney KB. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J Clin Lab Med 1976; 88: 118-24.
90. Chambers HF, Sande MA. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984; 26: 61-4.
91. Carrizosa J, Kobasa WD, Kaye D. Comparison of ceforanide, cefazolin, methicillin and nafcillin in S. aureus endocarditis therapy in rabbits. Antimicrob Agents Chemother 1980; 18: 562-5.
92. Carrizosa J, Santoro J, Kaye D. Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cephazolin and methicillin. Antimicrob Agents Chemother 1978; 13: 74-7.
93. Leder K, Turnidge JD, Korman TM, Grayson ML. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 1999; 43: 113-18.
94. Howden BP, Richards MJ. The efficacy of continuous infusion flucloxacillin in home based therapy for serious staphylococcal infections and cellulitis. J Antimicrob Chemother 2001; 48: 311-14.
95. Dodek P, Phillips P. Questionable history of immediate-type hypersensitivity to penicillin in staphylococcal endocarditis: treatment based on skin-test results versus empirical alternative treatment - a decision analysis. Clin Infect Dis 1999; 29: 1251-6.
96. Carrizosa J, Kobasa W, Kaye D. Effectiveness of nafcillin, methicillin, and cephalothin in experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1979; 15: 735-7.
97. Fong IW, Engelking ER, Kirby WMM. Relative inactivation by Staphylococcus aureus of eight cephalosporin antibiotics. Antimicrob Agents Chemother 1976; 9: 939-44.
98. Goldman PL, Petersdorf RG. Importance of β-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis 1980; 141: 331-7.
99. Quinn EL, Pohlod D, Madhavan T, Burch K, Fisher E, Cox F. Clinical experiences with cephazolin and other cephalosporins in bacterial endocarditis. J Infect Dis 1973; 1328 Suppl: S386-9.
100. Bryant RE, Alford RH. Unsuccessful treatment of staphylococcal endocarditis with cephazolin. JAMA 1977; 237: 569-70.
101. Nannini EC, Singh KV, Murray BE. Relapse of type A beta-lactamase- producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis 2003; 37: 1194-8.
102. Demin AA, Drobysheva VP. [Ceftriaxone in the treatment of staphylococcal endocarditis]. Antibiot Khimother 1998; 43: 12-15.
103. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34: 1227-31.
104. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17: 990-7.
105. McGrath BJ, Kang SL, Kaatz GW, Rybak MJ. Bactericidal activities of teicoplanin, vancomycin and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob Agents Chemother 1994; 38: 2034-40.
106. Kirby WMM. Vancomycin therapy in severe staphylococcal infections. Rev Infect Dis 1981; 3 Suppl 1: S236-9.
107. Geraci JE, Wilson WR. Vancomycin therapy for infective endocarditis. Rev Infect Dis 1981; 3 Suppl 1: S250-8.
108. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97: 344-50.
109. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109: 619-24.
110. Levine DP, Cushing RD, Jui J, Brown WJ. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982; 97: 330-8.
111. Levine DP, Fromm B, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
112. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-6.
113. Woods CW, Cheng AC, Fowler VG Jr, Moorefield M, Frederick J, Sakoulas G et al. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 38: 1189-91.
114. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
115. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous infusion vancomycin therapy for patients with suspected or documented Grampositive infections. Antimicrob Agents Chemother 1996; 40: 696-700.
116. De Gorgolas M, Aviles P, Verdejo C, Fernandez Guerrero ML. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin- resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 1995; 39: 953-7.
117. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990; 162: 103-8.
118. Cremieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989; 159: 938-44.
119. Glupczynski Y, Lagast H, Van der Auwera P, Thys JP, Crokaert F, Yourassowsky E et al. Clinical evaluation of teicoplanin for therapy of severe infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 1986; 29: 52-7.
120. Martino P, Venditti M, Micozzi A, Brandimatre C, Gentile G, Santini C et al. Teicoplanin in the treatment of Gram-positive bacterial endocarditis. Antimicrob Agents Chemother 1989; 33: 1329-34.
121. Leport C, Perronne C, Massip P, Canton P, LeClercq P, Bernard E et al. Evaluation of teicoplanin for treatment of endocarditis caused by Gram-positive cocci in 20 patients. Antimicrob Agents Chemother 1989; 33: 871-6.
122. Fortun J, Perez-Molina JA, Anon MT, Martinez-Beltran J, Loza E, Guerrero A. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrob Agents Chemother 1995; 39: 525-8.
123. Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother 1996; 38: 507-21.
124. Gilbert DN, Wood CA, Kimbrough RC. The Infectious Diseases Consortium of Oregon. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991; 35: 79-87.
125. Greenberg RN. Treatment of bone, joint, and vascular-access associated Gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990; 34: 2392-7.
126. Wilson APR, Gruneberg RN, Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother 1993; 32: 792-6.
127. Burch KH, Quinn EL, Cox F, Madhavan T, Fisher E, Romig D. Intramuscular clindamycin for therapy of infective endocarditis. Report of 23 cases and review of the literature. Am J Cardiol 1976; 38: 929-33.
128. Cherubin CE, Nair R. Clindamycin in infective endocarditis. JAMA 1978; 239: 626-7.
129. Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 1986; 30: 382-4.
130. Fernandez-Guerrero M, Rouse M, Henry N, Wilson W. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1988; 32: 747-51.
131. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental staphylococcal endocarditis. Antimicrob Agents Chemother 1989; 33: 1184-7.
132. Mulligan ME, Ruane PJ, Johnston L, Wong P, Wheelock JP, MacDonald K et al. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med 1987; 82: 215-19.
133. Entenza JM, Que YA, Vouillamoz J, Glauser MP, Moreillon P. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother 2001; 45: 3076-83.
134. Berrington AW, Koerner RJ, Perry JD, Bain HH, Gould FK. Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int J Med Microbiol 2001; 291: 237-9.
135. Chuard C, Herrmann M, Vadaux P, Waldvogel FA, Lew DP. Treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991; 35: 2611-16.
136. Zak O, Scheld WM, Sande MA. Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis 1983; 5: S481-90.
137. Turnidge J, Collingnon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12 Suppl 2: S35-44.
138. Whitby M. Fusidic acid in septicaemia and endocarditis. Int J Antimicrob Agents 1999; 12 Suppl 2: S17-22.
139. Humble MW, Eykeyn SJ, Phillips I. Staphylococcal bacteraemia, fusidic acid and jaundice. BMJ 1980; 280: 1495-8.
140. Eykyn SJ. Staphylococcal bacteraemia and endocarditis and fusidic acid. J Antimicrob Chemother 1990; 25: 33-8.
141. Gosden PE, Reeves BC, Osbourne JRS, Turner A, Millar M. Retrospective study of outcome in patients treated for Staphylococcus aureus bacteremia. Clin Microbiol Infect 1997; 3: 32-40.
142. Yeldandi V, Strodtman R, Lentino JR. In vitro and in vivo studies of trimethoprim-sulfamethoxazole against multiple-resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 22: 873-80.
143. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390-8.
144. Batard E, Jacqueline C, Boutoille D, Hamel A, Drugeon HB, Asseray N et al. Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study. Antimicrob Agents Chemother 2002; 46: 2174-8.
145. Carbon C. Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection. J Antimicrob Chemother 1997; 39 Suppl A: 115-19.
146. Vouillamoz J, Entenza JM, Feger C, Glauser MP, Moreillon P. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 2000; 44: 1789-95.
147. Pavie J, Lefort A, Zarrouk V, Chau F, Garry L, Leclercq R et al. Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics. Antimicrob Agents Chemother 2002; 46: 3061-4.
148. Zarrouk V, Bozdogan B, Leclercq R, Garry L, Feger C, Carbon C et al. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. Antimicrob Agents Chemother 2001; 45: 1244-8.
149. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18: 199-202.
150. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. For the Synercid Emergency-Use Study Group. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000; 46: 775-80.
151. Dailey CF, Dileto-Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH, Ford CW et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 2304-8.
152. Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL, Dailey CF, Ford CW, Batts DH et al. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 2001; 47: 349-52.
153. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 3002-4.
154. Dailey CF, Pagano PJ, Buchanan LV, Paquette JA, Haas JV, Gibson JK. Efficacy of linezolid plus rifampicin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2003; 47: 2655-8.
155. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002; 35: 1018-20.
156. Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50: 1017-26.
157. Andrade-Baiocchi S, Tognim MC, Baiocchi OC, Sader HS. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn Micro Infect Dis 2003; 45: 149-52.
158. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8.
159. Drinkovic D, Morris AJ, Pottumarthy S, MacCulloch D, West T. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J Antimicrob Chemother 2003; 52: 820-5.
160. Watanakunakorn C, Glotzbecker C. Enhancement of the effects of antistaphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother 1974; 6: 802-6.
161. Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 2002; 49: 437-44.
162. Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1990; 34: 2081-5.
163. Apellaniz G, Valdes M, Perez R, Martin F, Soria F, Garcia A et al. Comparison of the effectiveness of various antibiotics in the treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. J Chemother 1991; 3: 91-7.
164. Korzeniowski O, Sande MA, and the National Collaborative Endocarditis
165. Torres-Tortosa M, de Cueto M, Veegara A, Sanchez-Porto A, Perez-Guzman EP, Gonzalez-Serrano M et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Eur J Clin Microbiol Infect Dis 1994; 13: 559-64.
166. Fortun J, Navas E, Martinez-Beltran J, Perez-Molina J, Martin-Davila P, Guerrero A et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33: 120-5.
167. Abrams B, Sklaver A, Hoffman T, Greenman R. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med 1979; 90: 789-91.
168. Pittet D, Harding I. Infective endocarditis and glycopeptides. J Infect 1998; 37: 127-35.
169. Henry NK, Rouse MS, Whitesell AL, McConnell ME, Wilson WR. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987; 82 Suppl 4A: 73-5.
170. Dworkin RJ, Sande MA, Lee BL, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet, 1989; 2: 1071-3.
171. Peterson L, Quick J, Jensen B, Homann S, Johnson S, Tenquist J et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates: resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonization. Arch Intern Med 1990; 150: 2151-5.
172. Tebas P, Martinez Ruiz R, Roman F, Mendaza P, Rodriguez Diaz JC, Daza R et al. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis 1991; 163: 204-5.
173. Faville RJ Jr, Zaske DE, Kaplan EL, Crossley K, Sabath LD, Quie PG. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 1978; 240: 1963-5.
174. Simon GL, Smith RH, Sande MA. Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases. Rev Infect Dis 1983; 5: S507-8.
175. Kobasa WD, Kaye KL, Shapiro D, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983; 5: S533-7.
176. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiological and clinical observations as guides to therapy. Ann Intern Med 1983; 98: 447-55.
177. Yu VL, Fang G, Keys TF, Harris AA, Gentry LO, Fuchs PC et al. Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only. Ann Thorac Surg 1994; 58: 1073-7.
178. Tornos P, Sanz E, Permanyer-Miralda G, Almirante B, Planes AM, Soler-Soler J. Late prosthetic valve endocarditis: immediate and long term prognosis. Chest 1992; 101: 37-41.
179. Chirouze C, Cabell CH, Fowler VG Jr, Khayat N, Olaison L, Miro JM et al. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve endocarditis from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2004; 38: 1323-7.
180. Francioli PB. Ceftriaxone and outpatient treatment of infective endocarditis. Infect Dis Clin North Am 1993; 267: 279-80.
181. Stamboulian D. Outpatient treatment of endocarditis in a clinic-based program in Argentina. Eur J Clin Microbiol Infect Dis 1995; 14: 648-54.
182. Graninger W, Presterl E, Wenisch C, Schwameis E, Breyer S, Vukovich T. Management of serious staphylococcal infections in the outpatient setting. Drugs 1997; 54: 21-8.
183. Huminer D, Bishara J, Pitlik S. Home intravenous antibiotic therapy for patients with infective endocarditis. Eur J Clin Microbiol Infect Dis 1999; 18: 330-4.
184. Tice AD. Safety of outpatient parenteral antimicrobial therapy for endocarditis. Clin Infect Dis 2002; 34: 419-20.
185. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis 2001; 33: 203-9.
186. Steckelberg JM, Murphy JG, Ballard D, Bailey K, Tajik AJ, Taliercio CP et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 1991; 114: 635-40.
187. Williams DN, Rehm SJ, Tice AD, Bradley JS, Kind AC, Craig WA. Practice guidelines for community-based anti-infective therapy. Clin Infect Dis 1997; 25: 787-801.
188. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. Infect Dis Clin North Am 1998; 12: 879-901.
189. Visser LG, Arnouts P, van Furth R, Mattie H, van den Broek PJ. Clinical pharmacokinetics of continuous intravenous administration of penicillins. Clin Infect Dis 1993; 17: 491-5.
190. Meine TJ, Nettles RE, Anderson TJ, Cabell CH, Corey GR, Sexton DJ et al. Cardiac conduction abnormalities in endocarditis defined by the Duke criteria. Am Heart J 2001; 142: 280-5.
191. Sexton DJ, Spelman D. Current best practice and guidelines: assessment and management of complications in infective endocarditis. Infect Dis Clin North Am 2002; 16: 507-21.
192. Weinstein L. Life-threatening complications of infective endocarditis and their management. Arch Intern Med 1986; 146: 953-7.
193. Richardson JV, Karp RB, Kirklin JW, Dismukes WE. Treatment of infective endocarditis: a 10-year comparative analysis. Circulation 1978; 58: 589-97.
194. Croft CH, Woodward W, Elliott A, Commerford PJ, Barnard CN, Beck W. Analysis of surgical versus medical therapy in active complicated native valve endocarditis. Am J Cardiol 1983; 51: 1650-5.
195. Aguado J, Gonzalez-Vilchez F, Martin-Duran R, Arjona R, Vazquez de Prada JA. Perivavlular abscesses associated with endocarditis. Clinical features and diagnostic accuracy of two-dimensional echocardiography. Chest 1993; 104: 88-93.
196. Mathew J, Abreo G, Namburi K, Narra L, Franklin C. Results of surgical treatment for infective endocarditis in intravenous drug users. Chest 1995; 108: 73-7.
197. Roder BL, Wandall DA, Espersen F, Frimodt-Moller N, Skinhoj P, Rosdahl VT. A study of 47 bacteremic Staphylococcus aureus endocarditis cases: 23 with native valves treated surgically and 24 with prosthetic valves. Scand Cardiovasc J 1997; 31: 305-9.
198. Langley SM, Alexiou C, Stafford HM, Dalrymple-Hay MJ, Haw MP, Livesey SA et al. Aortic valve replacement for endocarditis: determinants of early and late outcome. J Heart Valve Dis 2000; 9: 697-704.
199. Bishara J, Leibovicci L, Gartman-Israel D, Sagie A, Kazakov A, Miroshnik E et al. Long-term outcome of infective endocarditis: the impact of surgical intervention. Clin Infect Dis 2001; 33: 1636-43.
200. Hendren WG, Morris AS, Rosenkranz ER, Lyttle BW, Taylor PC, Stewart WJ et al. Mitral valve repair for bacterial endocarditis. J Thorac Cardiovasc Surg 1992; 103: 124-9.
201. Arbulu A, Holmes RJ, Asfaw I. Tricuspid valvulectomy without replacement. Twenty years experience. J Thorac Cardiovasc Surg 1991; 102: 917-22.
202. Arbulu A, Holmes RJ, Asfaw I. Surgical treatment of intractable right-sided endocarditis in drug addicts: 25 years' experience. J Heart Valve Dis 1993; 2: 129-37.
203. Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Sullam PM, Filler SG et al. Acetylsalicylic acid reduces vegetation bacterial density, haematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 1999; 99: 2791-7.
204. Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R. Influence of adjunctive ticlodipine on the treatment of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents 1998; 9: 227-9.
205. Nicolau DP, Tessier PR, Nightingale CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents 1999; 11: 159-61.
206. Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Arch Intern Med 1999; 159: 473-5.
207. Salem DN, Daudelin D, Levine HJ, Pauker SG, Eckman MH, Riff J. Antithrombotic therapy in valvular heart disease. Chest 2001; 119: 207S-219S.